Compare · MRNA vs TWST
MRNA vs TWST
Side-by-side comparison of Moderna Inc. (MRNA) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $63.41B, about 6.3x TWST ($10.04B).
- TWST has been more active in the news (33 items in the past 4 weeks vs 10 for MRNA).
- MRNA has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- Moderna Inc.
- Twist Bioscience Corporation
- Price
- -
- -
- Market cap
- $63.41B
- $10.04B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 10
- 33
- Recent ratings
- 25
- 15
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest MRNA
- Moderna upgraded by Wolfe Research
- Moderna upgraded by BofA Securities
- Moderna upgraded by William Blair
- Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
- SEC Form SCHEDULE 13G filed by Moderna Inc.
- Chief Executive Officer Bancel Stephane exercised 751,715 shares at a strike of $19.15 and sold $28,715,011 worth of shares (499,246 units at $57.52) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 6,440,260 units (SEC Form 4) to satisfy withholding tax
- Amendment: SEC Form SCHEDULE 13G/A filed by Moderna Inc.
- Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
- SEC Form 144 filed by Moderna Inc.
- Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna's Investigational Vaccine Against Bundibugyo Ebolavirus
Latest TWST
- Officer Cho Dennis sold $222,227 worth of shares (1,598 units at $139.07), decreasing direct ownership by 2% to 74,063 units (SEC Form 4) to satisfy withholding tax
- President and COO Finn Patrick John sold $562,661 worth of shares (4,046 units at $139.07), decreasing direct ownership by 2% to 210,802 units (SEC Form 4) (tax withholding)
- Chief Accounting Officer Werner Robert F. sold $213,255 worth of shares (1,523 units at $140.02), decreasing direct ownership by 3% to 44,637 units (SEC Form 4) (withholding tax)
- Chief Financial Officer Laponis Adam sold $273,265 worth of shares (1,965 units at $139.07), decreasing direct ownership by 2% to 108,633 units (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Leproust Emily M. sold $923,259 worth of shares (6,639 units at $139.07), decreasing direct ownership by 0.81% to 812,299 units (SEC Form 4) to satisfy tax liability
- SVP of Human Resources Green Paula sold $189,130 worth of shares (1,360 units at $139.07), decreasing direct ownership by 1% to 117,921 units (SEC Form 4) (tax withholding)
- Officer Cho Dennis sold $1,843,099 worth of shares (14,205 units at $129.75) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 75,661 units (SEC Form 4)
- President and COO Finn Patrick John exercised 23,355 shares at a strike of $67.85 and sold $9,217,607 worth of shares (78,355 units at $117.64) as part of a pre-agreed trading plan, decreasing direct ownership by 20% to 214,678 units (SEC Form 4)
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation